Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT
13 Mai 2008 - 2:46AM
PR Newswire (US)
GAITHERSBURG, Md., May 12 /PRNewswire-FirstCall/ -- Iomai
Corporation (NASDAQ:IOMI) today said that it will host a conference
call and live webcast tomorrow to discuss today's announcement that
Intercell AG (VSE: ICLL) and Iomai have entered into a definitive
agreement pursuant to which Intercell will acquire Iomai for USD
6.60 per share representing a fully diluted equity value of
approximately USD 189 million (EUR 122 million). The conference
call and webcast will be held at 8:30 a.m. Eastern Time tomorrow,
Tuesday, May 13. Conference Call Details To access the live
conference call Tuesday, May 13, 2008 at 8:30 a.m. Eastern Time via
phone, please dial 866-713-8395 from the United States and Canada
or 617-597-5309 internationally. The conference ID is 32511819.
Please dial in approximately 10 minutes prior to the start of the
call. To access the live webcast, go to the Investor Relations
section of the Company's website at http://www.iomai.com/. Please
connect to the web site at least 15 minutes prior to the call to
allow for any software download that may be necessary. The webcast
is also being distributed through the Thomson StreetEvents Network.
Individual investors can listen to the call at
http://www.earnings.com/, Thomson's individual investor portal,
powered by StreetEvents. Institutional investors can access the
call via Thomson StreetEvents (http://www.streetevents.com/), a
password-protected event management site. ABOUT IOMAI CORPORATION
Iomai Corporation discovers and develops vaccines and immune system
stimulants, delivered via a novel, needle-free technology called
transcutaneous immunization (TCI). TCI taps into the unique
benefits of a major group of antigen-presenting cells found in the
outer layers of the skin (Langerhans cells) to generate an enhanced
immune response. Iomai is leveraging TCI to enhance the efficacy of
existing vaccines, develop new vaccines that are viable only
through transcutaneous administration and expand the global vaccine
market. Iomai currently has four product candidates in development:
three targeting influenza and pandemic flu and one to prevent E.
coli-related travelers' diarrhea. For more information on Iomai,
please visit http://www.iomai.com/. Additional Information and
Where to Find It In connection with the proposed transaction, Iomai
Corporation will be filing a proxy statement for its stockholders
and other documents regarding the proposed transaction with the
Securities and Exchange Commission (SEC). BEFORE MAKING ANY VOTING
OR INVESTMENT DECISION, IOMAI STOCKHOLDERS AND INVESTORS ARE URGED
TO READ THE PROXY STATEMENT AND OTHER RELEVANT MATERIALS CAREFULLY
IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THE DOCUMENTS
WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION
AND IOMAI. Investors and stockholders may obtain copies of the
proxy statement and other relevant documents filed with the SEC by
Iomai free of charge at the SEC's web site at http://www.sec.gov/.
In addition, investors and stockholders may obtain copies of the
proxy statement and other relevant documents filed with the SEC by
Iomai (when they are available) free of charge by going to Iomai's
Investor Relations page on its corporate website at
http://www.iomai.com/. Iomai and its directors, executive officers
and other members of management may be deemed to be participants in
the solicitation of proxies from Iomai's stockholders with respect
to the proposed transaction. Information regarding Iomai's
executive officers and directors, and their beneficial ownership of
Iomai's common stock as of March 26, 2008 is available in Iomai's
proxy statement for its 2008 Annual Meeting of Stockholders, which
was filed with the SEC on April 4, 2008. Other information
regarding the interests of such potential participants in the proxy
solicitation will be contained in the proxy statement and other
relevant materials to be filed with the SEC when they become
available. DATASOURCE: Iomai Corporation CONTACT: Russell P.
Wilson, Senior Vice President, Chief Financial Officer and General
Counsel of Iomai Corporation, +1-301-556-4478, ; or Brian Reid of
WeissComm Partners, Inc., +1-703-402-3626, , for Iomai Corporation
Web site: http://www.iomai.com/
Copyright
Iomai Corp (MM) (NASDAQ:IOMI)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Iomai Corp (MM) (NASDAQ:IOMI)
Historical Stock Chart
Von Sep 2023 bis Sep 2024
Echtzeit-Nachrichten über Iomai Corp (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Iomai (MM) News-Artikel